Nutex Health Swings to Profit on Soaring Hospital Revenue

TL;DR

NUTX is finally making money, but watch those arbitration costs and stock comp — it's a high-risk, high-reward play.

AI Summary

Nutex Health Inc. (NUTX) reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $163.749 million, a substantial improvement from a net loss of $4.698 million in the prior year. Total revenue surged to $723.578 million, up from $222.331 million, primarily driven by its hospital division which generated $700.488 million, compared to $199.367 million in 2024. The company's cash and cash equivalents dramatically increased to $166.048 million as of September 30, 2025, from $40.640 million at December 31, 2024. Operating income also saw a robust increase to $244.707 million from $16.412 million year-over-year. Key business changes include the continued operation of 24 hospital facilities across 11 states and growth in its population health management division, which contributed $23.090 million in revenue. Risks include significant accrued arbitration expenses of $64.313 million and substantial stock-based compensation expenses totaling $119.606 million for the nine-month period. The strategic outlook appears focused on expanding its hospital division and managing its physician networks.

Why It Matters

Nutex Health's dramatic shift from a net loss to a $163.749 million net income signals a potential turning point for investors, driven by its expanding hospital division. This performance could attract new capital and improve investor confidence, especially after two reverse stock splits in 2024 aimed at NASDAQ compliance. For employees and customers, the growth in hospital operations and physician networks suggests stability and potentially expanded services, while the competitive healthcare market will closely watch Nutex's ability to sustain this growth and manage its significant accrued arbitration expenses.

Risk Assessment

Risk Level: high — The risk level is high due to the significant accrued arbitration expenses of $64.313 million as of September 30, 2025, up from $47.742 million at December 31, 2024, indicating ongoing legal uncertainties. Additionally, stock-based compensation expense surged to $119.606 million for the nine months ended September 30, 2025, compared to $1.952 million in the prior year, which could dilute shareholder value and impact future profitability.

Analyst Insight

Investors should closely monitor the resolution of Nutex Health's accrued arbitration expenses and the impact of its high stock-based compensation on future earnings per share. While the revenue growth is impressive, a deeper dive into the sustainability of hospital division margins and the long-term implications of equity dilution is crucial before making a significant investment.

Financial Highlights

revenue

$723.578M

total Assets

$964.518M

total Debt

$43.578M

net Income

$163.749M

gross Margin

55.0%

cash Position

$166.048M

revenue Growth

+225.2%

Revenue Breakdown

Key Numbers

• $163.749M — Net Income (Swung from a $4.698M net loss in 2024 to a profit in 2025.)
• $723.578M — Total Revenue (Increased significantly from $222.331M in the prior year.)
• $166.048M — Cash and Cash Equivalents (Increased from $40.640M at December 31, 2024.)
• $64.313M — Accrued Arbitration Expenses (Increased from $47.742M at December 31, 2024, indicating ongoing legal risks.)
• $119.606M — Stock-Based Compensation (Massive increase from $1.952M in the prior year, impacting equity.)
• 24 — Hospital Facilities (Number of facilities operated by the hospital division across 11 states.)
• 7,071,916 — Common Stock Shares Outstanding (As of November 10, 2025, reflecting the impact of 2024 reverse stock splits.)
• $244.707M — Operating Income (Significantly up from $16.412M in the prior year, showing operational efficiency.)

Key Players & Entities

• Nutex Health Inc. (company) — registrant
• The NASDAQ Stock Market LLC (regulator) — exchange where common stock is registered
• Thomas Vo, M.D. (person) — Chairman and CEO of Nutex Health Inc.
• Clinigence Holdings, Inc. (company) — merged with Nutex Health Holdco LLC
• $163.749 million (dollar_amount) — Net income for the nine months ended September 30, 2025
• $723.578 million (dollar_amount) — Total revenue for the nine months ended September 30, 2025
• $64.313 million (dollar_amount) — Accrued arbitration expenses as of September 30, 2025
• $119.606 million (dollar_amount) — Stock-based compensation expense for the nine months ended September 30, 2025
• Houston, Texas (location) — Company's corporate headquarters
• Delaware (location) — State of incorporation for Nutex Health Inc.

FAQ

Risk Factors

• Accrued Arbitration Expenses [high — legal]: Accrued arbitration expenses increased to $64.313 million as of September 30, 2025, from $47.742 million at December 31, 2024. This indicates ongoing legal disputes and potential financial liabilities.
• Stock-Based Compensation Expenses [high — financial]: Stock-based compensation expenses for the nine months ended September 30, 2025, totaled $119.606 million, a substantial increase from $1.952 million in the prior year. This significantly impacts equity and earnings.
• Dependence on Hospital Division [medium — operational]: The company's revenue is heavily reliant on its hospital division, which generated $700.488 million out of $723.578 million in total revenue for the nine months ended September 30, 2025. Any disruption to these facilities could severely impact financial performance.
• Financing Lease Liabilities [medium — financial]: Significant financing lease liabilities, totaling $270.077 million net of current portion as of September 30, 2025, represent a substantial financial obligation. These leases are crucial for operations but add to leverage.
• Accounts Receivable Growth [medium — financial]: Accounts receivable increased to $387.409 million from $232.449 million, indicating a rise in revenue but also a potential increase in collection risk and working capital requirements.

Industry Context

Nutex Health operates within the healthcare services sector, specifically focusing on hospitals and population health management. The industry is characterized by increasing demand for healthcare services, evolving regulatory landscapes, and a trend towards value-based care models. Consolidation among providers and the integration of technology are also key trends impacting companies like Nutex.

Regulatory Implications

The healthcare industry is heavily regulated, with potential impacts from changes in healthcare laws, reimbursement policies (e.g., Medicare/Medicaid), and compliance requirements. Companies must navigate complex regulations related to patient care, billing, and data privacy, which can lead to significant compliance costs and potential penalties.

What Investors Should Do

1. Monitor arbitration expense trends
2. Analyze stock-based compensation impact
3. Evaluate revenue concentration
4. Assess cash flow generation and usage

Key Dates

• 2025-09-30: Nine Months Ended — Reported significant financial turnaround with net income of $163.749M and revenue of $723.578M.
• 2025-09-30: Balance Sheet Date — Cash and cash equivalents increased to $166.048M, while accrued arbitration expenses rose to $64.313M.
• 2024-12-31: Prior Year End — Provided a baseline for comparison, showing a net loss of $4.698M and cash of $40.640M.
• 2024-04-09: Reverse Stock Split — One of two reverse stock splits in 2024 that adjusted historical share counts and per-share data.
• 2024-07-02: Reverse Stock Split — The second reverse stock split in 2024, further adjusting share data for comparability.

Glossary

VIEs

Variable Interest Entities, which are entities that a company has a controlling financial interest in, even if it doesn't have majority voting rights. (Nutex Health Inc. consolidates these entities, meaning their financial results are included in the company's overall financial statements.)

2024 Reverse Stock Splits

Two stock consolidations (1-for-15 and 1-for-10) completed in 2024 to reduce the number of outstanding shares. (All historical share and per-share data presented in the report have been adjusted to reflect these splits for comparability.)

Accrued arbitration expenses

Expenses related to ongoing arbitration proceedings that have been recognized but not yet paid. (A significant and increasing liability ($64.313M) indicating potential future cash outflows and legal risks.)

Stock-based compensation

Compensation provided to employees and executives in the form of stock options or awards, rather than cash. (A substantial expense ($119.606M) for the nine-month period, impacting profitability and diluting existing shareholders.)

Financing lease liabilities

Obligations arising from leases that transfer substantially all the risks and rewards of ownership of an asset to the lessee. (Represents a significant financial commitment ($270.077M net) for assets used in operations.)

Noncontrolling interests

The portion of equity in a subsidiary that is not attributable to the parent company. (Indicates that Nutex Health does not own 100% of all its consolidated subsidiaries, with $120.867M attributed to other owners.)

Year-Over-Year Comparison

Nutex Health has demonstrated a dramatic financial improvement compared to the prior year. Total revenue has surged by 225.2% to $723.578 million, driven primarily by its hospital division. This revenue growth has translated into a significant swing from a net loss to a net income of $163.749 million. Operating income also saw a substantial increase from $16.412 million to $244.707 million. However, the company faces increased risks, notably a rise in accrued arbitration expenses to $64.313 million and a substantial increase in stock-based compensation expenses to $119.606 million, which were $1.952 million in the prior year.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value NUTX The NASDAQ Stock Market

Filing Documents

• nutx-20250930.htm (10-Q) — 1605KB
• nutx-2025x09x30xex311.htm (EX-31.1) — 10KB
• nutx-2025x09x30xex312.htm (EX-31.2) — 10KB
• nutx-2025x09x30xex321.htm (EX-32.1) — 5KB
• nutx-2025x09x30xex322.htm (EX-32.2) — 4KB
• nutx-20250930_g1.jpg (GRAPHIC) — 68KB
• 0001628280-25-053166.txt ( ) — 9584KB
• nutx-20250930.xsd (EX-101.SCH) — 73KB
• nutx-20250930_cal.xml (EX-101.CAL) — 86KB
• nutx-20250930_def.xml (EX-101.DEF) — 386KB
• nutx-20250930_lab.xml (EX-101.LAB) — 766KB
• nutx-20250930_pre.xml (EX-101.PRE) — 576KB
• nutx-20250930_htm.xml (XML) — 1463KB

— Financial Information

Part I — Financial Information Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets (unaudited) 5 Condensed Consolidated Statements of Operations (unaudited) 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) 7 Condensed Consolidated Statements of Cash Flows (unaudited ) 9 Notes to Condensed Consolidated Financial Statements (unaudited) 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 47 Item 4.

Controls and Procedures

Controls and Procedures 47

— Other Information

Part II — Other Information Item 1.

Legal Proceedings

Legal Proceedings 48 Item 1A.

Risk Factors

Risk Factors 49 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 51 Item 3. Defaults upon Senior Securities 51 Item 4. Mine Safety Disclosures 51 Item 5. Other Information 51 Item 6. Exhibits 52 Table of Contents INTRODUCTORY NOTE Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the "Company," "we," "us," "our," "Nutex" and similar words are references to Nutex Health Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities ("VIEs"). The Company effected two reverse stock splits of its common stock during 2024: a 1-for-15 reverse stock split effective April 9, 2024 and a 1-for-10 reverse stock split effective July 2, 2024 (the "2024 Reverse Stock Splits"). Unless otherwise indicated, all authorized, issued, and outstanding stock and per share amounts referred to in this Quarterly Report on Form 10-Q have been adjusted to reflect the 2024 Reverse Stock Splits for all prior periods presented. Proportionate adjustments for the 2024 Reverse Stock Splits were made to the exercise prices and number of shares issuable under the Company's equity incentive plans, and the number of shares underlying outstanding equity awards, as applicable. See Note 1 for information and disclosures relating to adjustments related to the 2024 Reverse Stock Splits. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, changes in laws or regulations applicable to our operations, an

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 4 Table of Contents NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 166,048 $ 40,640 Restricted short-term investments — 2,941 Accounts receivable 387,409 232,449 Accounts receivable - related parties 7,353 3,602 Inventories 3,158 2,850 Income tax receivable 12,097 — Prepaid expenses and other current assets 16,586 9,997 Total current assets 592,651 292,479 Property and equipment, net 82,821 77,933 Operating lease right-of-use assets 27,354 27,872 Financing lease right-of-use assets 225,719 218,889 Intangible assets, net 21,555 15,530 Goodwill, net 13,919 13,919 Deferred tax assets — 7,987 Other assets 499 711 Total assets $ 964,518 $ 655,320 Liabilities and Equity Current liabilities: Accounts payable $ 45,475 $ 9,614 Accounts payable - related parties 4,082 806 Lines of credit 5,304 3,554 Current portion of long-term debt 18,004 14,395 Operating lease liabilities, current portion 2,111 2,080 Financing lease liabilities, current portion 7,108 7,705 Accrued arbitration expenses 64,313 47,742 Accrued income tax expense — 26,533 Accrued stock-based compensation 11,194 16,356 Accrued expenses and other current liabilities 27,865 25,440 Total current liabilities 185,456 154,225 Long-term debt, net 25,574 22,466 Operating lease liabilities, net 30,423 30,617 Financing lease liabilities, net 270,077 259,479 Deferred tax liabilities 14,955 — Total liabilities 526,485 466,787 Commitments and contingencies (Note 10 ) Equity: Common stock, $ 0.001 par value; 950,000,000 shares authorized; 6,905,262 and 5,511,452 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 7 6 Additional paid-in capital 615,180 489,409 Accumulated deficit ( 298,021 ) ( 356,976 ) Nutex Health Inc. equity 317,166 132,439 Nonco

View Full Filing

View this 10-Q filing on SEC EDGAR